Results of a Prospective Non-Interventional Post-Authorization Safety Study of Idelalisib in Germany.
Saved in:
| Title: | Results of a Prospective Non-Interventional Post-Authorization Safety Study of Idelalisib in Germany. |
|---|---|
| Authors: | Hoechstetter MA; Department of Hematology, Oncology, Immunology, Palliative Medicine, Infectiology and Tropical Medicine, München Klinik Schwabing, Munich, Germany. Electronic address: manuela.hoechstetter@muenchen-klinik.de., Knauf W; Centrum für Hämatologie und Onkologie Bethanien, Hematology and Oncology Private Practice, Frankfurt, Germany., Dambacher S; Gilead Sciences, Inc., Foster City, California, USA., Hucke N; Gilead Sciences, Inc., Foster City, California, USA., Höhne K; Gilead Sciences, Inc., Foster City, California, USA., van Troostenburg A; Gilead Sciences, Inc., Foster City, California, USA., Ramroth H; Gilead Sciences, Inc., Foster City, California, USA., Abenhardt W; Hematology and Oncology Private Practice, Gilching, Germany., Rummel M; Department of Hematology and Oncology, University Hospital of the Justus-Liebig-University, Giessen, Germany. |
| Source: | Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2022 Aug; Vol. 22 (8), pp. e777-e787. Date of Electronic Publication: 2022 Apr 09. |
| Publication Type: | Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
